Yissum, the Technology Transfer Company of The Hebrew University of Jerusalem, has signed a strategic collaboration with KYORIN Pharmaceutical Co Ltd, a subsidiary of KYORIN Holdings Inc, it was reported yesterday.
The collaboration is aimed at the discovery of respiratory drug therapies.
Under the collaboration, KYORIN will sponsor a research programme led by Prof Francesca Levi-Schaffer of Hebrew University's Institute of Drug Research in the School of Pharmacy, Faculty of Medicine and advance its own drug discovery research. KYORIN and Prof Levi-Schaffer are to collaborate and screen for new drugs for the suppression of asthma and other related allergies.
Inimmune signs research collaboration with Boston Children's Hospital
ResVita Bio receives USD250,000 phase one Small Business Innovation Research grant from NIAID
Phase II Data of Oral Dexpramipexole Published in Eosinophilic Asthma
AllerVie Health Rebrands Southern Allergy & Asthma
Applied BioCode Inks Distribution Agreement with Medline Industries
Vedanta Biosciences Receives Fast Track Designation for VE303
KalVista Pharmaceuticals Presents Data at 13th C1-inhibitor Deficiency & Angioedema Workshop
French Ophthalmology Specialist Horus Pharma Group Launches a Nordic Subsidiary